J&J

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

CNN reports Johnson & Johnson is seeking an emergency authorization for its SARS-CoV-2 vaccine in the US.

Johnson & Johnson says its candidate SARS-CoV-2 vaccine has 66 percent efficacy rate in preventing moderate-to-severe COVID-19, according to NPR.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

Two coronavirus vaccine trials that had been paused in the US have resumed.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

Stat News reports Johnson & Johnson has paused its SARS-CoV-2 vaccine trial due to an unexplained illness affecting a study participant.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.